Although I haven't posted, I do follow the forum. I am still holding my shares and tempting to buy more. I am glad to see the clinical trials will be underway soon for the diagnostic machine. The reverse split was a good decision, as most institutional investor would like to see less floating shares and not trading a pennies. Hopefully, the new PR firm will do a better job. With most of shares locked up from directors, there is'nt much floating (just over 30 million). They also mentioned in the release that they plan to upgrade to a higher exchange (Nasdaq ?). I seee all these news release as positive.

The fact that Merck has not delivered yet, is not a reflection of Cardio's inability or mismanagement !! It is Merck that has been incompetent so far. But, maybe i am jumping to conclusion and the results of the new batches of beads are of good quality. You can't blame management for going to Merck, who (small cap) wouldn't.